“Neurofibromatosis 2Epidemiology” report has been recently added to DelveInsight
About Neurofibromatosis 2
Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas).
Request for free sample copy of Neurofibromatosis 2 epidemiology report- https://www.delveinsight.com/sample-request/neurofibromatosis-2-epidemiology-forecast
Neurofibromatosis 2 Epidemiology
DelveInsight’s ‘Neurofibromatosis 2 – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Neurofibromatosis 2 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Neurofibromatosis 2 Symptoms
The characteristic symptoms of NF2 usually develop around the time of puberty or during early adulthood. These symptoms may include problems with balance, buzzing or ringing in the ears (tinnitus), and/or gradual hearing loss. These symptoms usually result from the presence of benign tumors on both auditory nerves (acoustic neuromas vestibular schwannomas). Other tumors of the central nervous system may also develop, and can include neurofibromas, meningiomas, low grade gliomas (mainly benign ependymomas of the spinal cord), and schwannomas. The size, location, and number of tumors may vary in different people affected.
Neurofibromatosis 2 Causes
NF2 is caused by a mutation in the NF2 gene. The NF2 gene regulates (encodes for) the production of a protein known as merlin/schwannomin that plays a role in suppressing the development of certain tumors (tumor suppressor). According to investigators, merlin/schwannomin is related to a class of proteins (ezrin-radixin-moesin proteins) that serve to link the internal, supportive system within a cell (cytoskeleton) to proteins in cell membranes. Several different mutations of the NF2 gene have been identified in individuals with the disorder (e.g., deletions, nonsense and frameshift mutations).
Neurofibromatosis 2 Diagnosis
The diagnosis of NF2 is confirmed by a thorough clinical evaluation and specialized testing (i.e., CT scan, magnetic resonance imaging (MRI), pneumoencephalogram, or arteriogram are very rarely used nowadays). Molecular genetic testing for mutations in the NF2 gene is available for most affected individuals who have a positive family history.
Neurofibromatosis 2 Treatment
The treatment of vestibular (acoustic) neuromas associated with NF2 is the surgical removal of the tumors, when possible. The surgical procedure that is performed is based upon the size and precise location of the tumors. Radiation therapy may be considered for some individuals with this disorder, especially those who are not candidates for surgery. The VEGF inhibitor bevacizumab may also be considered to treat rapidly growing schwannomas but is very expensive.
Neurofibromatosis 2 Epidemiology: Report Scope
Following is the table of content of Neurofibromatosis 2 epidemiology report
1. Key Insights
2. Executive Summary of Neurofibromatosis 2
3. Neurofibromatosis 2: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
What are the important reasons to buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/